Janney Montgomery Scott LLC Makes New $1.45 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Janney Montgomery Scott LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 72,729 shares of the biotechnology company’s stock, valued at approximately $1,454,000.

A number of other institutional investors have also modified their holdings of the company. USA Financial Formulas grew its stake in ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 888 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 1,509 shares during the period. Quest Partners LLC acquired a new position in ADMA Biologics in the second quarter valued at $29,000. Finally, Arizona State Retirement System lifted its position in ADMA Biologics by 4.5% during the second quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,645 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $20.20 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64. The firm has a market capitalization of $4.71 billion, a P/E ratio of 73.18 and a beta of 0.64. The business’s 50-day simple moving average is $18.42 and its 200-day simple moving average is $14.22.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the previous year, the company posted $0.01 earnings per share. Equities analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on ADMA. HC Wainwright lifted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Insider Buying and Selling

In other news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 10.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The trade was a 19.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 466,900 shares of company stock valued at $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.